Join our email list to stay up to date on the latest Amyloidosis news.

A comprehensive report submitted to the FDA in 2016 by ARC. This is a detailed summary of the patient testimony presented at the Patient-Focused Drug Development meeting. This report will serve a critical function in communicating to both FDA review staff and industry the improvements that patients want and hope to see in their daily lives.

 

 

*

*

*

*